Abstracts tagged "Polymyositis/dermatomyositis (PM/DM) and pulmonary complications"

Abstract Number: 2168 • 2017 ACR/ARHP Annual Meeting
Dissociation of FVC and Dlco in Patients with Dermatomyositis and Polymyositis
Eun Hye Park¹, Woo Chang Hwang², Eun Young Lee¹, Eun Bong Lee¹, Yeong Wook Song³ and Jin Kyun Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Department of Statistics, Data Science for Knowledge Creation Research Center, Seoul National University, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Korea, Republic of (South)
Background/Purpose: Interstitial lung disease in patients with polymyositis (PM) and dermatomyositis (DM) is characterized by decrease in both lung compliance and pulmonary vascularity, leading to…
Abstract Number: 2075 • 2013 ACR/ARHP Annual Meeting
Analysis Of The Associations Between Serum Ferritin and Cytokines In Pulmonary Disease Activity With Polymyositis/Dermatomyositis
Hidenaga Kawasumi, Takahisa Gono, Yasushi Kawaguchi, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Polymyositis (PM) / dermatomyositis (DM) is occasionally complicated by interstitial lung disease (ILD), and ILD is a prognostic factor in PM/DM. We previously reported…
Abstract Number: 214 • 2012 ACR/ARHP Annual Meeting
Inflammatory Muscle Disease Associated Pulmonary Hypertension – Clinical Features and Survival At a National Referral Centre
Matthew Webber¹, D. Dobarro¹, Clive Handler², Christopher P. Denton³, Benjamin E. Schreiber⁴ and John G. Coghlan⁵, ¹Pulmonary Hypertension, Royal Free Hospital, London, United Kingdom, ²Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁴Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ⁵National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: The association between connective tissue disease (CTD) and pulmonary hypertension (PH) is well known, especially in the scleroderma population. However, the association between inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].